Last reviewed · How we verify
Gemcitabine and Erlotinib
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR).
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). Used for Pancreatic cancer, Non-small cell lung cancer.
At a glance
| Generic name | Gemcitabine and Erlotinib |
|---|---|
| Also known as | Gemcitabine and Tarceva |
| Sponsor | Grupo Espanol Multidisciplinario del Cancer Digestivo |
| Drug class | Nucleoside analog and tyrosine kinase inhibitor |
| Target | DNA and EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine works by incorporating itself into DNA, causing DNA damage and inhibiting cancer cell growth. Erlotinib, on the other hand, binds to the EGFR, preventing the receptor from activating downstream signaling pathways that promote cell proliferation and survival.
Approved indications
- Pancreatic cancer
- Non-small cell lung cancer
Common side effects
- Nausea
- Fatigue
- Diarrhea
- Rash
- Anemia
Key clinical trials
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (PHASE1)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
- Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery (PHASE3)
- Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (PHASE2)
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (PHASE2)
- Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: